893 related articles for article (PubMed ID: 37578234)
1. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
2. Cross-Neutralization of SARS-CoV-2-Specific Antibodies in Convalescent and Immunized Human Sera against the Bat and Pangolin Coronaviruses.
Srisutthisamphan K; Saenboonrueng J; Wanitchang A; Viriyakitkosol R; Jongkaewwattana A
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016415
[TBL] [Abstract][Full Text] [Related]
3. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
4. Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution.
Zhang S; Qiao S; Yu J; Zeng J; Shan S; Tian L; Lan J; Zhang L; Wang X
Nat Commun; 2021 Mar; 12(1):1607. PubMed ID: 33707453
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
6. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
[TBL] [Abstract][Full Text] [Related]
7. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin.
Niu S; Wang J; Bai B; Wu L; Zheng A; Chen Q; Du P; Han P; Zhang Y; Jia Y; Qiao C; Qi J; Tian WX; Wang HW; Wang Q; Gao GF
EMBO J; 2021 Aug; 40(16):e107786. PubMed ID: 34018203
[TBL] [Abstract][Full Text] [Related]
9. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
11. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
12. A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice.
Liu MQ; Lin HF; Li J; Chen Y; Luo Y; Zhang W; Hu B; Tian FJ; Hu YJ; Liu YJ; Jiang RD; Gong QC; Li A; Guo ZS; Li B; Yang XL; Tong YG; Shi ZL
J Virol; 2023 Feb; 97(2):e0171922. PubMed ID: 36688655
[TBL] [Abstract][Full Text] [Related]
13. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
[TBL] [Abstract][Full Text] [Related]
16. The Glycan-Binding Trait of the Sarbecovirus Spike N-Terminal Domain Reveals an Evolutionary Footprint.
Guo H; Li A; Lin HF; Liu MQ; Chen J; Jiang TT; Li B; Wang Y; Letko MC; Peng W; Shi ZL
J Virol; 2022 Aug; 96(15):e0095822. PubMed ID: 35852351
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
18. Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants.
Li B; Zhao Y; Wu X; Wu H; Tang W; Yu X; Mou J; Tan W; Jin M; Li W; Zhang Q; Liu M
ACS Nano; 2023 Apr; 17(7):7017-7034. PubMed ID: 36971310
[TBL] [Abstract][Full Text] [Related]
19. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
